OMNIAB INC (OABI) Stock Price & Overview
NASDAQ:OABI • US68218J1034
The current stock price of OABI is 1.79 USD. Today OABI is down by -3.24%. In the past month the price increased by 8.82%. In the past year, price decreased by -44.11%.
OABI Key Statistics
- Market Cap
- 257.688M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.57
- Dividend Yield
- N/A
OABI Stock Performance
OABI Stock Chart
OABI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to OABI. When comparing the yearly performance of all stocks, OABI is a bad performer in the overall market: 88.25% of all stocks are doing better.
OABI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OABI. No worries on liquidiy or solvency for OABI as it has an excellent financial health rating, but there are worries on the profitability.
OABI Earnings
On March 4, 2026 OABI reported an EPS of -0.11 and a revenue of 8.38M. The company missed EPS expectations (-21.76% surprise) and missed revenue expectations (-8.79% surprise).
OABI Forecast & Estimates
13 analysts have analysed OABI and the average price target is 7.48 USD. This implies a price increase of 317.88% is expected in the next year compared to the current price of 1.79.
For the next year, analysts expect an EPS growth of 29.32% and a revenue growth 66.2% for OABI
OABI Groups
Sector & Classification
OABI Financial Highlights
Over the last trailing twelve months OABI reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.53% | ||
| ROE | -24.26% | ||
| Debt/Equity | 0 |
OABI Ownership
OABI Latest News, Press Relases and Analysis
OABI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 18.72 | 176.784B | ||
| DHR | DANAHER CORP | 22.06 | 131.712B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 126.64 | 43.04B | ||
| A | AGILENT TECHNOLOGIES INC | 16.67 | 31.558B | ||
| WAT | WATERS CORP | 19.72 | 27.794B | ||
| IQV | IQVIA HOLDINGS INC | 12.85 | 27.351B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 25.03 | 23.745B | ||
| ILMN | ILLUMINA INC | 22.73 | 17.669B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 29.06 | 16.643B | ||
| MEDP | MEDPACE HOLDINGS INC | 25.84 | 12.597B | ||
| RVTY | REVVITY INC | 15.52 | 9.476B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 8.854B | ||
| TECH | BIO-TECHNE CORP | 22.85 | 8.052B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OABI
Company Profile
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 114 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Company Info
IPO: 2020-10-09
OMNIAB INC
5980 Horton Street, Suite 600
Emeryville CALIFORNIA US
Employees: 114
Phone: 15102507800
OMNIAB INC / OABI FAQ
What does OMNIAB INC do?
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 114 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Can you provide the latest stock price for OMNIAB INC?
The current stock price of OABI is 1.79 USD. The price decreased by -3.24% in the last trading session.
Does OMNIAB INC pay dividends?
OABI does not pay a dividend.
What is the ChartMill rating of OMNIAB INC stock?
OABI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is OMNIAB INC (OABI) expected to grow?
The Revenue of OMNIAB INC (OABI) is expected to grow by 66.2% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for OABI stock?
OMNIAB INC (OABI) currently has 114 employees.